Article

The cyclooxygenase-2-765C promoter polymorphism protects against the development of chronic obstructive pulmonary disease.

Department of Pharmacology & Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.
Respiratory medicine (impact factor: 2.33). 03/2011; 105(3):506-10. DOI:10.1016/j.rmed.2010.08.002 pp.506-10
Source: PubMed

ABSTRACT Susceptibility to Chronic Obstructive Pulmonary Disease (COPD) has a genetic component. We undertook a study to determine if a genetic variant of the gene encoding the cyclooxygenase-2 gene influences the likelihood of developing COPD.
In a case control study the frequency of a single nucleotide polymorphism in the promoter region of the cyclooxygenase-2 gene (-765 G → C) was determined in 205 subjects with COPD, 171 chronic smokers with normal lung function (resistant smokers) and 95 healthy blood donors using the polymerase chain reaction and restriction enzyme fragment length polymorphism.
The frequency of the C allele of the -765 cyclooxygenase-2 polymorphism was higher in resistant smokers (24.6%) compared with subjects with COPD (14.4%, OR = 1.98, 95% CI = 1.28-3.06, p = 0.003) and blood donors (14.7%, OR = 1.97, 95% CI = 1.14-3.41, p = 0.03).
The -765C allele, which has been shown to be associated with decreased promoter activity of the cyclooxygenase-2 gene, is more common in resistant smokers. This raises the possibility that decreased activity of cyclooxygenase-2 may protect smokers against the development of COPD.

0 0
 · 
0 Bookmarks
 · 
24 Views

Keywords

-765 cyclooxygenase-2 polymorphism
 
171 chronic smokers
 
95 healthy blood donors
 
blood donors
 
Chronic Obstructive Pulmonary Disease
 
common
 
COPD
 
cyclooxygenase-2 gene
 
cyclooxygenase-2 gene influences
 
decreased activity
 
gene encoding
 
genetic component
 
genetic variant
 
polymerase chain reaction
 
promoter activity
 
resistant smokers
 
restriction enzyme fragment length polymorphism
 
smokers
 

Lian Wu